- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
PMCPA case AUTH/2998/12/17 (Director v Lilly) concerning clinical trial disclosure for Cyramza. The matter was found to be outwith the scope of…
A public complaint about clinical trial disclosure for Lyxumia was ruled outwith the scope of the ABPI Code (2012). No case report…
A member of the public complained to the PMCPA about clinical trial disclosure for Cimzia. The matter was deemed outwith the scope…
Former employee challenged MSD internal memos about an audit protocol and a field-force briefing on Schering-Plough PDMs. Panel found the communications were…
A GP alleged an Ipsen rep implied Decapeptyl could be used beyond its licence by describing use when cancer had spread beyond…
A GP complained after a care home duty manager asked for BuTrans. PMCPA found no public advertising breach, but ruled the leavepiece…
A GP complained that a Cipralex cost bar chart implied generic competitor prices but actually used branded prices. The Panel said the…
A PCT complained a sponsored ‘Primary Care Report’ looked like disguised promotion for Clenil Modulite and misquoted DoH policy. The PMCPA Panel…
Anonymous GP alleged free-loan I-neb nebulisers with Promixin were an inducement and that reps made unproven dose-equivalence claims. Panel found the package…
Allergan press-release content placed in trade journals implied Bocouture/Xeomin was less potent than Vistabel/Botox. PMCPA ruled breach of undertaking (Clause 25) and…
Anonymous GP complaint about a product standardization programme in Northern Ireland. Case did not go before the Panel; programme already withdrawn. No…
A complaint about a Novartis tweet relating to liver disease. The PMCPA concluded no breach because the matter was outwith the scope…
Complaint alleged Lilly bypassed hospital pharmacy governance in a compassionate supply of Olumiant and risked patient safety. Panel found supply ultimately went…
PMCPA case AUTH/2899/11/16 (Director v Aegerion) concerning clinical trial disclosure for Lojuxta. Outcome: No breach and outwith the scope of the Code.
A POM ad for Ilube on a journal bellyband was visible through a transparent postal wrapper. PMCPA ruled this amounted to promotion…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.